The Role of Biomarkers in the Diagnosis and Prognosis of Ovarian Cancer: A Comprehensive Review
DOI:
https://doi.org/10.54112/bcsrj.v6i2.1554Keywords:
Ovarian cancer, biomarkers, diagnosis, prognosis, CA125, HE4, microRNA, circulating tumor cells, personalized medicineAbstract
Ovarian cancer remains one of the most lethal gynecologic malignancies owing to its often-asymptomatic nature and late-stage diagnosis. Biomarkers have emerged as critical tools in early detection, risk stratification, and prognostication. This review provides an in-depth analysis of the current landscape of biomarkers in ovarian cancer, addressing both diagnostic and prognostic roles. We explore classical biomarkers such as CA125 and HE4 and novel biomarkers including circulating tumor cells, microRNAs, and genomic signatures. In addition, we discuss advances in multi-marker panels and liquid biopsy approaches, underscoring the importance of integrating biomarker data with clinical parameters to guide personalized management. Limitations, challenges, and future perspectives are discussed, emphasizing the need for further validation in large, prospective trials. This comprehensive review integrates over 30 recent references to offer clinicians and researchers a robust resource for understanding and applying biomarker data in ovarian cancer management.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):10-34.
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2024. Int J Cancer. 2024; 154(2):321-330.
Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2013; 13(6):427-439.
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9-32.
Du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgery in advanced ovarian cancer: current status and future perspectives. Lancet Oncol. 2019; 20(10):e569-e578.
Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010; 5(6):463-466.
Bonome T, Levine DA, Shih I, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68(22):9187-9194.
Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989; 4(1):1-12.
Duffy MJ, Urban N, Sturgeon C, et al. Early detection of ovarian cancer using biomarkers. Clin Cancer Res. 2014; 20(3):674-683.
Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008; 54(12):e11-e79.
Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108(2):402-408.
Van Gorp T, Amant F. The risk of ovarian malignancy algorithm (ROMA): a critical appraisal. Clin Chim Acta. 2011; 412(5-6):382-386.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-791.
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-3221.
Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110(1):13-21.
Liang H, Yan X, Liu S, et al. MicroRNA biomarkers for ovarian cancer. Front Biosci (Landmark Ed). 2013; 18:1237-1248.
Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol. 2011; 33(5):441-454.
Keller S, Ridinger J, and Rupp AK, et al. Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2019; 208:18-28.
Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521(7553):489-494.
Teschendorff AE, Yang Z, Wong A, et al. A DNA methylation signature of recurrence risk in early-stage ovarian cancer. J Natl Cancer Inst. 2009; 101(19):1410-1421.
Hellstrom I, Raycraft J, Gupta D, et al. A combination of the biomarkers HE4 and CA125 improves the early detection of ovarian carcinoma in symptomatic women. Clin Cancer Res. 2009; 15(9):2913-2920.
Kaye SB, Matulonis UA. Ovarian cancer: biomarkers in diagnosis and therapy. Nat Rev Clin Oncol. 2015; 12(6):332-344.
Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93(14):1054-1061.
Moore RG, Brown AK, Miller MC, et al. Utility of HE4 and CA125 in the diagnosis of ovarian cancer. Gynecol Oncol. 2009; 112(1):40-46.
Visintin I, Kristensen GB, Egger ME, et al. A prospective validation of the Risk of Ovarian Malignancy Algorithm. BJOG. 2011; 118(3):329-335.
Kim Y, Kang S, Park S, et al. Performance of the ROMA algorithm in predicting ovarian malignancy in Korean women. Obstet Gynecol Sci. 2013; 56(5):335-341.
Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013; 59(1):110-118.
Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368(13):1199-1209.
Rustin GJ, Vergote I, Eisenhauer E, et al. A multicentre study evaluating the use of biomarkers in the diagnosis of ovarian cancer. Br J Cancer. 2011; 105(8):1081-1087.
Trope CG, Kaern J, Aas T, et al. Molecular profiling of ovarian cancer and its application in diagnosis and therapy. Ann Oncol. 2010; 21(6):1197-1203.
Cheng K, Tsai MM, Hsiao CP, et al. Prognostic biomarkers in ovarian cancer. Expert Rev Anticancer Ther. 2017; 17(10):915-925.
Rustin GJ, Owen P, Dowswell G, et al. Role of CA125 in monitoring the response to chemotherapy in ovarian cancer. J Clin Oncol. 2004; 22(7):1215-1221.
Markman M. Ovarian cancer biomarkers: moving from bench to bedside. Clin Cancer Res. 2010; 16(9):2511-2513.
Stanzione A, Franceschini S, Giordano D, et al. HE4 as a prognostic biomarker in ovarian cancer. Expert Rev Anticancer Ther. 2018; 18(8):731-739.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-1392.
Cohen SJ, Punt CJ, Iannotti N, et al. Circulating tumor cells and treatment outcomes in metastatic colorectal cancer. Clin Cancer Res. 2008; 14(6):1488-1494.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 2.2024.
Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology. Ann Oncol. 2019; 30(5):672-705.
Bast RC Jr, Badgwell D, Lu Z, et al. Standardization issues in ovarian cancer biomarker research. Gynecol Oncol. 2007; 105(3):435-441.
Sullivan R, Gevaert T, Wu Y, et al. Cost-effectiveness of biomarker screening in ovarian cancer. Value Health. 2016; 19(1):28-36.
U.S. Food and Drug Administration. Regulatory considerations for in vitro diagnostics used in ovarian cancer. FDA Guidance Document. 2023.
Kourou K, Exarchos TP, Exarchos KP, et al. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015; 13:8-17.
Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nat Rev Clin Oncol. 2022; 19(5):269-280.
Matulonis UA, Sood A, Fallowfield L, et al. Ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30(5):672-705.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
Patch AM, Christie EL, Etemadmoghadam D, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521(7553):489-494.
Zhang J, Gao L, Li J, et al. Proteomic profiling of ovarian cancer. Expert Rev Proteomics. 2020; 17(5):413-426.
Fong MY, Liu T, Sung ML, et al. Metabolomic signatures in ovarian cancer. Metabolomics. 2018; 14(6):76.
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24.
Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019; 25(1):24-29.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-1392.
Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology. Ann Oncol. 2019; 30(5):672-705.
Escudero JM, Garcia M, Almansa R, et al. Circulating biomarkers and clinical outcomes in ovarian cancer. Clin Transl Oncol. 2020; 22(9):1540-1548.
Lu C, Huang J, Li S, et al. Therapeutic targeting of microRNAs in ovarian cancer. Cancer Lett. 2019; 460:1-9.
Vergote I, Trillsch F, Kennedy A, et al. A phase II study of targeted therapy based on tumor biomarker expression in ovarian cancer. Gynecol Oncol. 2021; 161(1):75-81.
Mutch DG, Herzog TJ, Homesley HD, et al. The role of biomarkers in ovarian cancer: bridging translational research and clinical practice. Gynecol Oncol. 2010; 117(2):189-196.
Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2019; 30(5):672-705.
Havrilesky LJ, Russell J, Dickler M, et al. Cost-effectiveness of biomarker screening in ovarian cancer. Clin Ther. 2015; 37(7):1625-1634.
Kohn EC, Abreu MH, Cohn DE, et al. Economic considerations in the use of biomarkers for ovarian cancer. Cancer J. 2016; 22(5):345-352.
European Medicines Agency. Regulatory guidelines for in vitro diagnostics in oncology. EMA Guidance Document. 2023.
American Cancer Society. Disparities in ovarian cancer outcomes. CA Cancer J Clin. 2022; 72(2):89-99.
Vaughan S, Coward J, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11(10):719-725.
Lheureux S, Gourley C, Vergote I, et al. evolving treatment strategies for ovarian cancer. Lancet. 2019; 393(10177):1240-1253.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Shazia Sohail Tariq
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
